Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 study of Humalutin, a chimeric anti-CD37 Antibody Radionuclide Conjugate (ARC) in Non-Hodgkin's-lymphoma.

Next Previous
X
Search
Trial Profile

A Phase 1 study of Humalutin, a chimeric anti-CD37 Antibody Radionuclide Conjugate (ARC) in Non-Hodgkin's-lymphoma.

Status: Suspended
Phase of Trial: Phase I

Latest Information Update: 11 Apr 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Chimeric-anti-CD37-Antibody-Radionuclide-Conjugate (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions

    • Most Recent Events

    • 04 Apr 2018 According to a Nordic Nanovector media release, due to the revised timelines for the company's PARADIGME study and the need to conserve cash until it's data read-out, company has decided to put this phase 1 study on hold.
    • 04 Apr 2018 Status changed from planning to suspended, according to a Nordic Nanovector media release.
    • 15 Mar 2018 According to a Nordic Nanovector media release, the trial is expected to begin in 2H 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top